be_ixf;ym_202112 d_03; ct_50

Select Page

Latest Insights on ADGI

omicron Adagio Therapeutics A Stock-Picking Mutation to Beat the Omicron Threat
by Ted Bauman November 30, 2021 Bauman Daily, Global Economy, News
This is a company that has never made a profit. In fact, it’s never made any money at all. On top of that, analysts expect its per-share losses to double by the end of 2022. Assuming Adagio manages to generate some revenues next year — the market consensus is a minuscule $151 million — it’s already trading at almost 20 times those sales. Why? Because COVID is here to stay … and the search for a response is moving into new areas … quickly.
2022 stock predictions 5 Bold Predictions for 2022 and Beyond These will be the biggest growth themes for 2022.
bitcoin vs gold Are You Buying Bitcoin or Gold? Ian King and Steve Fernandez discuss why bitcoin could replace gold as the world’s store of value.

Newsletter Sign Up

Sponsored

MEET OUR EXPERTS

WHAT READERS ARE SAYING..

“I'm very Happy with your services. I hope you don't plan to retire any time soon! My retirement portfolio depends on your expert guidance. Keep up the great work! Thanks.”

- Randy

“Paul, your investment research has been a godsend. Our portfolio was just a tad over two million dollars. I paid my daughter's legal fees, my wife's medical expenses, helped my wife's stepmother with home repairs, loaned our son money for real estate. I also bought two used vehicles, one for our daughter and one for our eldest grandson. All told, these expenses added up to well over a quarter million dollars. I am happy to report that we have profits left over!”

- Taylor M.

“Paul, in September of 2017, I decided to go ‘all in’ on my stock positions and follow the portfolios in your services. My account value was $335,000. As of today, it totals 1.1 million dollars! Yes, that’s tripling my money in less than 3 years.”

- Suzie M.

Share This